news
Screening by compound activity could accelerate drug discovery
Researchers have developed a new screening technique called biological activity-based modelling to identify drug candidates.
List view / Grid view
Hit-to-Lead
news
Hymecromone can suppress neuroinflammation in astrocytes, study shows
Researchers have found that the spasmolytic drug hymecromone can suppress astrocyte inflammatory responses, meaning it could be used to combat Alzheimer's disease.
whitepaper
ebook: Revolutionise your lab with a cutting-edge bioprocess platform to drive quality and efficiency
With the right solution organisations can simplify their lab-based working, while ensuring the highest level of compliance with regulatory requirements.
whitepaper
Whitepaper: Biomarkers and mechanisms of toxicity
Phenotypic profiling identifies biomarkers and mechanisms of toxicity.
news
Screening of approved drugs reveals potential treatment for COVID-19
Vascor (bepridil) could be used to treat COVID-19, according to a new study which screened drugs to repurpose against SARS-CoV-2.
news
Experimental mAb subdues type 1 diabetes in laboratory mice
A monoclonal antibody given to mice reversed type 1 diabetes by suppressing the actions of glucagon, a study has shown.
news
Team modifies therapeutic molecule to improve stroke treatment
Researchers have shown that adding a polymer to glutamate-oxaloacetate transaminase means the molecule can treat stroke for up to six days in rats.
news
New nanotherapy could potential treat Crohn’s disease in children
A novel nanotherapy can decrease intestinal inflammation and shrink lesions in rodent models of Crohn's disease, a study has shown.
news
New drug combination could combat Diffuse Intrinsic Pontine Glioma
The drug combination of difluoromethylornithine and AMXT 1501 has shown success against Diffuse Intrinsic Pontine Glioma in animal models.
article
Advancing neutralising antibody therapies for COVID-19
In this article, Ian Chan, Chief Executive Officer and Co-Founder of biotech company Abpro, discusses the development of neutralising antibodies for SARS-CoV-2. Abpro’s neutralising antibody candidate ABP 300 is currently in Phase II/III trials.
news
Machine learning identifies drugs to repurpose against COVID-19
A team has developed a machine learning approach to screen for and identify drugs that could be repurposed against COVID-19 in the elderly.
whitepaper
ebook: Vaccines in the digital age
In this ebook, we’ll see how digitally enabling your organisation can increase capacity and improve vaccine production.
news
ProAgio drug shows success against solid tumours in mice
Studies in mice have shown that the drug ProAgio is effective at treating pancreatic cancer and triple-negative breast cancer.
whitepaper
Whitepaper: Profiling oncology candidates
Profiling oncology drug candidates through complementary in vitro assays and in vivo models to better understand their potential clinical applications.
news
New small molecules can prevent filovirus infection in cells
Through a series of experiments, researchers have identified small drug molecules that can inhibit filoviruses such as Ebola and Marburg.
